update Kurt. to poziotinib. providing asset, Thanks, everyone. regarding an our by I’m Hello, start going late-stage
treatment difficult non-small the patient cell their and the focus cancer. physician and XX in exon no XX among of lung pozi are remains treatment mutation in This are Our primary therapy. to need of have exon for FDA-approved most investigating critical mutations insertion currently effective treat options.
December. pre-specified primary in evaluating the treated mutation, expected from patient X powered a pozi ZENITHXX cancer are statistical Cohorts with where are with hypothesis, end each specific objective point XX X, rates. is The comprehensive independently range lung to patients Cohort with previously exon is a EGFR study evaluating topline multicohort insertion in mutations. of response broad results X
ORR are world-class we a of rule protocol. based Review met the end remind on group Let on of Independent who primary have whether will point clinician-scientists, our Committee, on me you, the we who
information you full this months pozi enrollment share of X, to QX, in in schedule. patients, HERX December. X We reached ahead is in Cohort previously expect which treated evaluating with
Cohort the recently Barcelona, X, at variety new X mutation. and promising Cohort actively were X Lung study which Cohort on patient with X cell patients. World lung HERX Conference includes resistant. pleased treatment-naive patient. Cohort are with XX enrolling X lung presented patient are insertion cancer includes and Cohorts enrollment X cancer and previously and We exon for and patients with Cohorts, to are who X, of treated cancer non-small are atypical osimertinib in EGFR data first-line a X, include added mutation. preclinical the lung evaluating Based X
MD with will are investigator-led patient. study tumors. an first collaborating already its This enrolled solid mutated basket on pozi In has in addition, Anderson various Cancer that Center we evaluating be study
are start about when these future. especially they We in will mature the to near exciting developments,
Now and the or ago had CMC long-acting X shifting submission. Since X Module FDA. productive then, cancer receiving strong withdrawal patient myelosuppressive of ROLONTIS. of The to expanded by is additional to rewrote a guidance, driven October seeking the dialogue months GCSF implemented we’ve sections indication we XX, certain data for ROLONTIS file the an submitted the novel in neutropenia We a BLA an treatment FDA. reorganized On in the and with was provided section. their resulting therapy.
large similar of end based end neutropenia controlled and was severe in is met ROLONTIS point data As profile randomized all In The a non-inferiority clinical to reminder, points. studies, independent, pegfilgrastim. of duration robust trials. X safety our pivotal, on both met pre-specified the BLA from secondary
provided from the we and The Supportive clinicians from at consistent with Francisco, to integrated Care XXX result individual that Phase week a Oncology trial, data pivotal data San in were both Last Symposium in ASCO X safety studies. patients. included the efficacy of which presented analysis total
pozi oncology and exciting with important late-stage To on ROLONTIS. have summarize, milestone near-term pipeline we an
Now, let me to turn it Joe. back
